In Brief: Abbott Outlook; CFSAN’s Landa To Retire; FTC Claim Substantiation
This article was originally published in The Tan Sheet
Executive Summary
Abbott “on track” in China recovery; CFSAN seeks new director; FTC adds new substantiation elements to settlement; NAD advises iSatori to amend claims energy supplement claims; FDA wants proof deficiencies are corrected; and FDA warns about chelation supplement.
You may also be interested in...
Fair Standard Remains For Supplement, Drug Claim Substantiation – FTC
The Federal Trade Commission says consent orders that require more clinical tests to substantiate health claims than are required for other product categories are fair because they are based on the nature of the claims, agency officials say.
Omega-3 Probe Underscores FTC Standard For Claims Substantiation
FTC's widespread review of omega-3 fatty acid supplement claims reminds firms they must support claims with "competent and reliable scientific evidence," a standard stakeholders argue is unclear and at times impractical
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.